Obstetrics and Gynecology & Clinical Laboratory | Prof. Wang Jianliu’s Team and Prof. Wang Hui’s Team Win the Chinese Preventive Medicine Association Science and Technology Award
王建六团队、王辉团队荣获中华预防医学会科学技术奖
2024-04-24
On
March 19, 2024, the Chinese Preventive Medicine Association (CPMA) announced
the winners of the 2023 Science and Technology Awards. Among them, research
teams from Peking University People’s Hospital (PKUPH) secured two awards:
Professor Wang Jianliu's team won the first prize, while Professor Wang Hui's
team clinched the second prize.
The
"CPMA Science and Technology Award" is the premier recognition in
public health and preventive medicine, presented by the National Office for
Science and Technology Awards in 2006. The award is evaluated and awarded every
two years. It has received recognition among professionals and is one of the
top three science and technology awards in the field of health and family
planning.
Professor
Wang Jianliu's Team: Precision Prevention and Treatment System for Endometrial
Cancer
Endometrial
cancer incidence in the United States has been rapidly rising in recent years
specifically with a trend towards younger adults. This team has spearheaded
comprehensive research for over two decades, yielding significant
breakthroughs:
1.
Investigated and applied molecular mechanisms related to estrogen-progesterone
imbalance and metabolic disorder, especially in glucose and lipid metabolism in
endometrial cancer pathogenesis for clinical treatment, to provide strategies
for primary prevention
2.
Devised a rapid endometrial cancer screening and diagnostic system, integrating
artificial intelligence and minimally invasive techniques for early detection
and treatment optimization, contributing to secondary prevention.
3.
Established a precision prognosis warning model based on molecular and clinical
pathological characteristics, realizing the hierarchical management of
low-risk, medium-risk and high-risk patients, and offering a novel tertiary
prevention approach for endometrial cancer.
(Key
members: Wang Jianliu, Wei Lihui, Li Qiling, Wang Zhiqi, Dong Yangyang, Zhang
Guo, Cheng Yuan, Li Xingchen, Liang Sichen, Wang Yiqin, Tian Li, Fan Yuan, Zhou
Jingyi, Hao Juan, Zhao Lijun.)
Professor
Wang Hui's Team: Epidemiology and Precision Diagnosis of Clinically Important
Pathogenic Microorganisms
Antimicrobial Resistance is a major public health challenge. This project has focused on China's clinically important pathogenic microorganisms' epidemiology and precision diagnosis, mapping drug-resistant bacteria spectrum from patient data. The team reported China's first case of super yeast Candida auris, elucidated new drug-resistant clone origins and evolution, and identified novel drug-resistant mechanisms and genes, providing new targets for the development of new drugs for multidrug-resistant bacteria. Their pioneering in vitro evaluation system for domestic new drugs and precision diagnosis platform based on metagenomic sequencing for lung and bloodstream infection pathogens have overcome significant technical hurdles.
Their findings have influenced domestic and international guidelines on drug-resistant bacteria control, enhancing clinical testing for domestic pathogens and facilitating effective drug-resistant bacteria control in China.
(Key
members: Wang Hui, Zhang Yawei, Wang Xiaojuan, Chen Hongbin, Li Henan, Wang Qi,
Wang Ruobing, Yin Yuyao, Jin Longyang, Guo Yifan.)
News Sources: the Department of Obstetrics & Gynecology, the Department of Clinical Laboratory
Rewritten by Gao Yanbing
Thanks for the assistance in proofreading from the Department of Obstetrics & Gynecology.
